Johnson & Johnson (JNJ) Stock Analysis & News The Ultimate Dividend King

Stock Rating: BUY | Dividend Safety: A+ | Fair Value: $165

Johnson & Johnson (NYSE: JNJ) stands as one of the world’s most respected healthcare companies and newly achieved 63 consecutive years of dividend increases, cementing its status as an elite Dividend King with an AAA credit rating—one of only two U.S. companies maintaining this distinction.

This comprehensive JNJ stock analysis examines the company’s healthcare fortress, pharmaceutical pipeline, dividend sustainability, growth prospects, and investment recommendation for 2026.

Executive Summary: JNJ Stock at a Glance

Current Stock Data (January 2026):

• Stock Price: $207 range
• 52-Week Range: $140.68 – $215.19
• Market Cap: $489 billion
• Dividend Yield: 2.51%
• Annual Dividend: $5.20 per share ($1.30 quarterly)
• Dividend Growth (5Y CAGR): 5.3%
• Payout Ratio: 49%

Investment Recommendation: BUY

JNJ represents blue-chip quality at fair valuation. As one of only two U.S. companies maintaining AAA credit rating alongside Microsoft, Johnson & Johnson combines pharmaceutical innovation with medical device leadership while delivering reliable 2.51% yield backed by 63 years of consecutive dividend increases. The Kenvue separation simplified the business, positioning J&J for accelerated growth in high-margin innovative medicines and medical technology.

Price Targets:

• Bear Case: $175 (15% downside)
• Base Case: $230 (11% upside)
• Bull Case: $260 (26% upside)

JNJ Stock Key Metrics Dashboard

Metric	Value	Industry Avg	Assessment
Valuation
P/E Ratio (TTM)	24.53x	22x	Fair
Forward P/E	16.2x	18x	Undervalued
P/E vs 5Y Avg	24.5x vs 17.8x	–	Premium
Price/Sales	5.2x	4.1x	Premium
EV/EBITDA	14.8x	13.5x	Reasonable

Profitability

Operating Margin	32.1%	24%	Excellent
Net Margin	19.5%	16%	Superior
ROE	25%+	18%	Outstanding
ROIC	18%	12%	Exceptional

Financial Health

Credit Rating	AAA	A+	Best-in-Class
Debt/Equity	0.47	0.75	Conservative
Current Ratio	1.32	1.5	Adequate
Interest Coverage	15.2x	8x	Excellent

Dividend Metrics

Dividend Yield	2.51%	1.5%	Attractive
Payout Ratio	49%	60%	Conservative
5Y Div. Growth	5.3%	4%	Strong
Consecutive Increases	63 years	–	Dividend King

Growth

Revenue Growth (FY2024)	2.51%	1.5%	Attractive
EPS Growth (5Y)	49%	60%	Conservative
Guided 2026 Growth	5%+	–	Accelerating

What is JNJ? Business Model Overview

Johnson & Johnson is a diversified healthcare giant operating through two core segments following the November 2023 spin-off of consumer health business Kenvue.

Founded in 1886, J&J built an empire on the “Credo” philosophy prioritizing patients, employees, communities, and shareholders—in that order. This values-driven approach created one of the world’s most trusted healthcare brands.

The JNJ Business Model Post-Kenvue

Two Operating Segments:

1. Innovative Medicine (64% of revenue, ~70% of profit): Develops and markets pharmaceutical products across immunology, oncology, neuroscience, cardiovascular/metabolism, and pulmonary hypertension.

Blockbuster Drugs:

• STELARA (immunology): $10+ billion annual sales treating Crohn’s disease, ulcerative colitis, psoriasis
• DARZALEX (oncology): $9+ billion, multiple myeloma treatment showing 40%+ growth
• TREMFYA (immunology): $3+ billion, psoriasis treatment with 40% growth rate
• ERLEADA (oncology): $2+ billion, prostate cancer treatment
• INVEGA SUSTENNA/TRINZA (neuroscience): $4+ billion, schizophrenia treatment

Pipeline Highlights:

• 11 brands with double-digit growth rates
• Ublituximab for multiple sclerosis
• TAR-200 for bladder cancer (projected $5 billion asset)
• Tec-Dara combination therapies

2. MedTech (36% of revenue, ~30% of profit): Develops medical devices and diagnostic products across orthopedics, surgery, interventional solutions, and vision.

Key Products:

• Hip and knee implants (orthopedics)
• Surgical instruments and robotics
• Contact lenses (Acuvue brand)
• Electrophysiology devices
• Biosense Webster cardiac mapping

Innovation Focus:

• OTTAVA general surgery robotic system (FDA IDE approved)
• Advanced wound closure devices
• Next-generation cardiac mapping technology

Competitive Advantages (Economic Moat)

1. Pharmaceutical Pipeline Depth: J&J maintains one of industry’s deepest pipelines with 60+ compounds in clinical development. This diversified pipeline reduces dependence on any single drug’s success.

2. Patent Cliffs Managed Through Diversification: Unlike pure-play pharma facing patent cliffs on 1-2 blockbusters, J&J’s 20+ major products spread patent expiration risk over decades.

3. AAA Credit Rating: Only 2 U.S. companies maintain AAA rating (J&J and Microsoft). This fortress balance sheet enables acquisitions, R&D investment, and dividend security unmatched in healthcare.

4. Regulatory Expertise: 138 years of FDA engagement create institutional knowledge navigating complex approvals. J&J’s track record speeds time-to-market for innovations.

5. Global Scale & Distribution: Operations in 260 countries with established relationships enable rapid new product launches globally.

6. Brand Trust: Despite talc litigation, J&J brand maintains exceptional trust in healthcare. Hospitals, doctors, and patients rely on J&J quality.

JNJ Dividend Analysis: Yield, Growth & Safety

JNJ’s dividend credentials are unparalleled—63 consecutive years of increases with AAA credit rating backing payments.

Current Dividend Metrics

Annual Dividend: $5.20 per share
Quarterly Dividend: $1.30
Dividend Yield: 2.51%
Payment Frequency: Quarterly (March, June, September, December)
Last Ex-Dividend Date: November 25, 2025
Next Payment Date: March 10, 2026

Dividend Growth History

Historical Dividend Growth Rates:

• 1-Year: 5.1%
• 3-Year CAGR: 5.8%
• 5-Year CAGR: 5.3%
• 10-Year CAGR: 6.1%

The company announced its 63rd consecutive annual increase in 2025, an achievement shared by fewer than 50 companies worldwide.

Recent Dividend History:

• 2026: $5.20 (current, +5.1%)
• 2025: $4.95 (+5.3%)
• 2024: $4.70 (+5.8%)
• 2023: $4.44 (+6.6%)
• 2022: $4.16 (+6.6%)
• 2021: $4.04 (+5.0%)

Dividend Sustainability: Grade A+

Payout Ratio: 49%

J&J’s conservative 49% payout ratio ranks among the lowest of Dividend Kings, providing exceptional safety margins. This leaves 51% of earnings for R&D, acquisitions, and business growth.

Free Cash Flow Coverage: 1.8x

J&J generates approximately $18-20 billion annual free cash flow against $12.6 billion in dividend payments, providing robust 1.8x coverage.

Earnings Coverage: 2.0x

With adjusted EPS near $10.50 and annual dividends of $5.20, earnings cover dividends 2.0x—well within sustainable ranges.

AAA Credit Rating: As one of only two U.S. companies with AAA rating, J&J possesses financial fortress enabling dividend payments through any economic scenario. The company maintained dividends through 2008 crisis, 2020 pandemic, and every recession since 1963.

Why the A+ Rating?

J&J earns rare A+ dividend safety rating based on:

1. 63-Year Track Record: Uninterrupted increases since 1963
2. AAA Credit Rating: Best-in-class financial strength
3. 49% Payout Ratio: Among lowest of all Dividend Kings
4. 1.8x FCF Coverage: Exceptional cash generation
5. Diversified Revenue: Pharma + MedTech reduces single-product risk
6. Essential Healthcare: Recession-resistant demand

The only scenario threatening J&J’s dividend would be unprecedented multi-decade pharmaceutical innovation failure combined with MedTech collapse—exceedingly unlikely.

Dividend Growth Outlook

Projected Dividend Increases:

• 2027: $5.47 (+5.2%)
• 2028: $5.75 (+5.1%)
• 2029: $6.05 (+5.2%)
• 2030: $6.36 (+5.1%)

At historical 5.3% growth rates, J&J’s dividend reaches $6.70 by 2030, providing 3.2% yield on cost for today’s buyers at $207.

Comparison to Healthcare Dividend Peers

Company	Yield	Growth	Payout	Years	Credit	Grade
JNJ	2.51%	5.3%	49%	63	AAA	A+
Pfizer (PFE)	6.4%	0%	85%	15	A	B
Merck (MRK)	3.4%	5.1%	50%	14	AA-	A-
AbbVie (ABBV)	3.6%	8%	45%	52	BBB+	A-
Eli Lilly (LLY)	0.7%	15%	25%	10	AA	B+

JNJ offers the best combination of safety, longevity, and reliability among large-cap pharma.

JNJ Stock Financial Analysis

FY2024 Results (ended December 31, 2024):

• Revenue: $88.8 billion (up 4.3%)
• Operational Growth: 5.9%
• Adjusted EPS: $9.98
• Net Earnings: $14.0 billion

Q3 2025 Results:

• Revenue: $24.0 billion (up 5.4% operational)
• Innovative Medicine: +5.3% with 11 double-digit growth brands
• MedTech: +5.6% operational growth
• Adjusted EPS: $2.80 (beat $2.76 estimate)

Annual Revenue Progression:

• FY2024: $88.8 billion (+4.3%)
• FY2023: $85.2 billion (+6.5%)
• FY2022: $94.9 billion (includes consumer)
• FY2021: $93.8 billion

5-Year Revenue CAGR (continuing operations): 5.1%

2026 Guidance & Outlook

Management Guidance:

• Revenue Growth: Exceeding 5% operational
• EPS: Expected to top consensus estimates
• Key Drivers: Pipeline launches, DARZALEX expansion, MedTech innovation

This guidance represents acceleration from FY2024’s 4.3% growth, reflecting:

1. Kenvue separation clarity
2. New product launches
3. Market share gains
4. Pricing discipline

JNJ Stock Valuation Analysis

Current Valuation Metrics:

• P/E Ratio (TTM): 24.53x
• Forward P/E: 16.2x
• 5-Year Average P/E: 17.8x
• PEG Ratio: 3.2 (elevated)

DCF Fair Value: $230 per share

Using conservative assumptions:

• Revenue growth: 4-5%
• EBIT margin: 32-33%
• Terminal growth: 3%
• WACC: 7.5%

This suggests 11% upside from current $207 levels.

JNJ Growth Catalysts

1. Pharmaceutical Pipeline 60+ compounds in development across oncology, immunology, neuroscience

2. DARZALEX Expansion
40% growth rate, expanding indications, combination therapies

3. TAR-200 Bladder Cancer Projected $5 billion blockbuster launching 2026-2027

4. MedTech Robotics OTTAVA surgical system competing with Intuitive Surgical

5. Emerging Markets Growing middle class in Asia, Latin America driving healthcare demand

JNJ Risks

1. Talc Litigation Multi-billion dollar legal exposure from talc-related claims

2. Patent Expirations STELARA loses exclusivity creating headwinds

3. Pricing Pressure Medicare negotiation, generic competition

4. R&D Execution Pipeline failures could impact growth trajectory

JNJ Investment Recommendation

Overall Rating: BUY

Johnson & Johnson represents blue-chip quality at fair valuation for conservative dividend investors.

Bull Case Price Target: $260 (26% upside)
Base Case Price Target: $230 (11% upside)
Bear Case Price Target: $175 (15% downside)

The asymmetric risk/reward favors long-term positions, particularly for dividend-focused portfolios prioritizing safety and reliability.

Read More

1. Dividend Kings List 2026
2. 10 Best Dividend Stocks 2026
3. 8 Best Dividend Growth Stocks 2026
4. 7 Best Dividend Aristocrats

JNJ Stock FAQs

Is JNJ a good dividend stock?

Yes, JNJ is one of the best dividend stocks available. With 63 consecutive years of dividend increases, AAA credit rating, 2.51% yield, and 49% payout ratio, Johnson & Johnson provides unmatched dividend safety and reliability backed by diversified healthcare businesses generating consistent cash flow.

What is JNJ’s dividend yield?

JNJ’s current dividend yield is 2.51%, paying $5.20 annually ($1.30 quarterly). This yield exceeds the S&P 500’s 1.5% average while maintaining conservative 49% payout ratio ensuring sustainability.

Does JNJ increase its dividend?

Yes, JNJ has increased its dividend for 63 consecutive years (since 1963), qualifying as an elite Dividend King. The company typically announces increases in April with 5-6% annual growth rates, demonstrating unwavering commitment to shareholder returns.

Is JNJ overvalued?

JNJ trades at fair value near $207. Forward P/E of 16.2x sits below 5-year average of 17.8x, while DCF analysis suggests fair value of $230 (11% upside). The AAA credit rating and Dividend King status justify premium valuations.

Should I buy JNJ stock now?

Yes, JNJ represents a BUY for dividend growth and blue-chip investors. Trading at fair valuation with 63-year dividend streak, AAA rating, and accelerating growth from pipeline launches, Johnson & Johnson offers attractive risk/reward for long-term portfolios.

Conclusion

Johnson & Johnson stands as the ultimate healthcare dividend fortress—combining 63 years of dividend increases with AAA credit rating, diversified pharmaceutical/MedTech operations, and deep pipeline generating future growth.

Rating: BUY | Price Target: $230 | Dividend Safety: A+

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. JNJ stock faces pharmaceutical, litigation, and regulatory risks. Conduct thorough research before investing.